Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models for Pulmonary Infection Treatments
Summary
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to develop machine learning models and enhance physiologically based pharmacokinetics / pharmacodynamics (PBPK/PD) approaches for potential treatments of pulmonary infections. “Significant investments have been made by our partner to identify new oral and/or intravenous therapies for the lung, which will make our technology a centerpiece of their research strategy and enable accurate first-in-human predictions based on in silico, in vitro, and preclinical data,” said Dr. Viera Lukacova, chief scientist at Simulations Plus. Additionally, the innovative GastroPlus PBPK/PD models will be validated in specific populations (e.g., disease, geriatric) and published to increase regulatory understanding and acceptance.” “This new collaboration highlights the uniqueness of working with Simulations Plus,” added John DiBella, Lancaster division president for the company. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide.
Classifications
AskAI Classifications
LabelsLinked Companies
